National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2012 - specification under subsection 84AAA(2) (No. PB 24 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L00710

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
 
COMMONWEALTH OF AUSTRALIA
Instrument number PB 24 of 2012
National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2012 - specification under subsection 84AAA(2)1
 
Amendment determination under subsection 84AAA(2) of the National Health Act 1953
 
I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
 
Dated         23 March 2012
 
 
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
 
 
 
Amendment determination — Pharmaceutical Benefits - Early Supply
 
 
1          Name of Instrument
 
(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2012 - specification under subsection 84AAA(2).
 
(2)           This Instrument may also be cited as No. PB 24 of 2012.
 
2          Commencement
 
This Instrument commences on 1 April 2012.
 
 
3          Amendment of PB 30 of 2009
 
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2), PB 30 of 2009.
 
Schedule 1        Amendments
[1]                       Schedule 1, before item dealing with Aciclovir
insert in the columns in the order indicated:
 
Abatacept
Injection 125 mg in 1 mL single dose pre-filled syringe
Injection
4
5
 
 
[2]                       Schedule 1, after item dealing with Nifedipine
insert in the columns in the order indicated:
 
Nilotinib
Capsule 150 mg (as hydrochloride monohydrate)    
Oral
120
5
 
 
[3]                       Schedule 1, item dealing with Oestradiol
Omit from the columns in the order indicated:
 
 
Transdermal patches 8 mg, 8
Transdermal
1
5
 
 
[4]                       Schedule 1, item dealing with Nilotinib, Capsule 200 mg (as hydrochloride monohydrate)
omit from the column headed “Maximum quantity or number of units”:
112
and substitute:
120
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.